{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:23:22Z","timestamp":1793413402297,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.lanmic.2025.101181","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:44:11Z","timestamp":1758789851000},"page":"101181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["WHO global gonococcal antimicrobial surveillance programmes, 2019\u201322: a retrospective observational study"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-2081","authenticated-orcid":false,"given":"Magnus","family":"Unemo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M","family":"Lahra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle J","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0530-7357","authenticated-orcid":false,"given":"Daniel","family":"Marcano Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Jacobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Galarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5284-9960","authenticated-orcid":false,"given":"Kristen M","family":"Kreisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Galas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bertagnolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Ramon-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Maatouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Wi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2025.101181_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","article-title":"Gonorrhoea","volume":"5","author":"Unemo","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.lanmic.2025.101181_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41579-024-01023-3","article-title":"Antimicrobial treatment and resistance in sexually transmitted bacterial infections","volume":"22","author":"Jensen","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.lanmic.2025.101181_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002344","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action","volume":"14","author":"Wi","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.lanmic.2025.101181_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1071\/SH19023","article-title":"World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts","volume":"16","author":"Unemo","year":"2019","journal-title":"Sex Health"},{"key":"10.1016\/j.lanmic.2025.101181_bib6","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","article-title":"WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017\u201318: a retrospective observational study","volume":"2","author":"Unemo","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2025.101181_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/IM9.0000000000000113","article-title":"Global transmission of the penA allele 60.001-containing high-level ceftriaxone-resistant gonococcal FC428 clone and antimicrobial therapy of associated cases: a review","volume":"5","author":"van der Veen","year":"2023","journal-title":"Infect Microb Dis"},{"key":"10.1016\/j.lanmic.2025.101181_bib8","article-title":"The WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) identifies high levels of ceftriaxone resistance across Vietnam, 2023","volume":"48","author":"Lan","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.lanmic.2025.101181_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/mra.01231-23","article-title":"Complete reference genomes of two ceftriaxone-resistant Neisseria gonorrhoeae strains identified in routine surveillance in Bangkok, Thailand, using Nanopore Q20+ chemistry, VolTRAX V2b, and Illumina sequencing","volume":"13","author":"Sangprasert","year":"2024","journal-title":"Microbiol Resour Announc"},{"key":"10.1016\/j.lanmic.2025.101181_bib10","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.8.1900118","article-title":"Genetic relatedness of ceftriaxone-resistant and high-level azithromycin resistant Neisseria gonorrhoeae cases, United Kingdom and Australia, February to April 2018","volume":"24","author":"Jennison","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.lanmic.2025.101181_bib11","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.24.2200455","article-title":"Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022","volume":"27","author":"Pleininger","year":"2022","journal-title":"Euro Surveill"},{"key":"10.1016\/j.lanmic.2025.101181_bib12","article-title":"High prevalence of ceftriaxone-resistant and XDR Neisseria gonorrhoeae in several cities of Cambodia, 2022\u201323: WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP)","volume":"6","author":"Ouk","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.lanmic.2025.101181_bib13","series-title":"Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae","year":"2012"},{"key":"10.1016\/j.lanmic.2025.101181_bib15","series-title":"Global action plan on antimicrobial resistance","year":"2015"},{"key":"10.1016\/j.lanmic.2025.101181_bib16","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/jac\/dkae176","article-title":"The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains\u2013phenotypic, genetic and reference genome characterisation","volume":"79","author":"Unemo","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanmic.2025.101181_bib19","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2025.101181_bib20","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2025.101181_bib21","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","article-title":"Postexposure doxycycline to prevent bacterial sexually transmitted infections","volume":"388","author":"Luetkemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2025.101181_bib22","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1093\/jac\/dkae369","article-title":"Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015\u201324: an observational analysis","volume":"79","author":"Fifer","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanmic.2025.101181_bib23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/jac\/dkae063","article-title":"Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125\u20131 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea","volume":"79","author":"Unemo","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanmic.2025.101181_bib24","article-title":"2020 European guideline for the diagnosis and treatment of gonorrhoea in adults","volume":"29","author":"Unemo","year":"2020","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.lanmic.2025.101181_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/jac\/dkac366","article-title":"GyrB in silico mining in 27\u2009151 global gonococcal genomes from 1928\u20132021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility","volume":"78","author":"Golparian","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanmic.2025.101181_bib26","article-title":"Pharmacodynamic evaluation of zoliflodacin treatment of Neisseria gonorrhoeae strains with amino acid substitutions in the zoliflodacin target GyrB using a dynamic hollow fiber infection model","volume":"13","author":"Jacobsson","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lanmic.2025.101181_bib27","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1093\/jac\/dky162","article-title":"In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae","volume":"73","author":"Jacobsson","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanmic.2025.101181_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-18","article-title":"Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae","volume":"62","author":"Scangarella-Oman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2025.101181_bib29","article-title":"High susceptibility to the novel antimicrobial zoliflodacin among Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021\u20132024","volume":"15","author":"Jacobsson","year":"2025","journal-title":"IJID Reg"},{"key":"10.1016\/j.lanmic.2025.101181_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01497-17","article-title":"In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae","volume":"61","author":"Jacobsson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2025.101181_bib31","article-title":"Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections","volume":"13","author":"Jacobsson","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lanmic.2025.101181_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00521-20","article-title":"Relationship between gepotidacin exposure and prevention of on-therapy resistance amplification in a Neisseria gonorrhoeae hollow-fiber in vitro infection model","volume":"64","author":"VanScoy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2025.101181_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.682135","article-title":"Pharmacodynamic evaluation of dosing, bacterial kill, and resistance suppression for zoliflodacin against Neisseria gonorrhoeae in a dynamic hollow fiber infection model","volume":"12","author":"Jacobsson","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lanmic.2025.101181_bib34","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.vaccine.2023.01.053","article-title":"Vaccine value profile for Neisseria gonorrhoeae","volume":"42","author":"Lyu","year":"2024","journal-title":"Vaccine"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524725001090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524725001090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:40:48Z","timestamp":1760074848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524725001090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666524725001090"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2025.101181","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WHO global gonococcal antimicrobial surveillance programmes, 2019\u201322: a retrospective observational study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2025.101181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101181"}}